On the 18th, the 99th regular shareholders' meeting is being held at the auditorium of Yuhan Corporation headquarters in Daebang-dong, Dongjak-gu, Seoul. (Photo by Yuhan Corporation)

On the 18th, the 99th regular shareholders' meeting is being held at the auditorium of Yuhan Corporation headquarters in Daebang-dong, Dongjak-gu, Seoul. (Photo by Yuhan Corporation)

View original image

[Asia Economy Reporter Lee Chun-hee] Yuhan Corporation announced on the 18th that it held the 99th Annual General Meeting of Shareholders at its headquarters auditorium in Daebang-dong, Dongjak-gu, Seoul on the morning of the 18th.


At the shareholders' meeting, Yuhan Corporation reported last year's separate financial results of 1,624.133 billion KRW in revenue, operating profit of 61.71 billion KRW, and net profit of 113.866 billion KRW.


President Cho Wook-je said in his greeting, “Despite the difficult environment amid the COVID-19 pandemic crisis, all Yuhan employees achieved balanced growth across all sectors based on the One Team spirit,” and added, “Led by the global innovative new drug 'Reclaza,' we will continue to advance toward Yuhan’s vision of ‘Great Yuhan, Global Yuhan’ and the creation of Yuhan’s 100-year history.”



In the agenda review, a cash dividend of 400 KRW per common share and 410 KRW per preferred share (totaling 26 billion KRW) was decided.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing